Arcturus Therapeutics Holdings (ARCT) Free Cash Flow (2018 - 2026)

Arcturus Therapeutics Holdings (ARCT) has 9 years of Free Cash Flow data on file, last reported at -$19.4 million in Q1 2026.

• Quarterly Free Cash Flow rose 44.89% year-over-year to -$19.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$58.7 million (up 34.72% YoY) and the FY2025 annual result came in at -$74.5 million, down 23.36% from the prior year.
• Free Cash Flow retreated to -$19.4 million in Q1 2026, from -$16.1 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $163.6 million in Q4 2022 to a low of -$51.2 million in Q1 2022.
• A 5-year average of -$8.5 million and a median of -$19.4 million in 2026 frame the typical range for Free Cash Flow.
• Annual changes were most pronounced in 2022 — Free Cash Flow surged 485.04% — and 2025, when it plunged 5582.75%.
• Tracing ARCT's Free Cash Flow over 5 years: stood at $163.6 million in 2022, then slumped by 100.92% to -$1.5 million in 2023, then surged by 81.12% to -$284000.0 in 2024, then sank by 5582.75% to -$16.1 million in 2025, then decreased by 20.46% to -$19.4 million in 2026.
• The last three Free Cash Flow figures came in at -$19.4 million (Q1 2026), -$16.1 million (Q4 2025), and -$17.3 million (Q3 2025), per Business Quant data.